Confirmatory interleukin-1 receptor antagonist trial in severe sepsis

医学 安慰剂 感染性休克 中期分析 败血症 多中心试验 随机对照试验 内科学 休克(循环) 死亡率 麻醉 多中心研究 病理 替代医学
作者
Steven M. Opal,Charles J. Fisher,Jean-François Dhainaut,Jean‐Louis Vincent,Rainer Brase,Stephen F. Lowry,Jerald C. Sadoff,Gus J. Slotman,Howard Levy,R.A. Balk,M. P. Shelly,John P. Pribble,J.F. LaBrecque,Janice L. Lookabaugh,Heidi Donovan,Howard V. Dubin,Robert P. Baughman,James Norman,Eric J. DeMaria,Klaus E. Matzel,Edward Abraham,Michael G. Seneff
出处
期刊:Critical Care Medicine [Ovid Technologies (Wolters Kluwer)]
卷期号:25 (7): 1115-1124 被引量:769
标识
DOI:10.1097/00003246-199707000-00010
摘要

To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis.Prospective, randomized, double-blind, placebo-controlled, multicenter trial with a planned, midstudy, interim analysis.Ninety-one academic medical center intensive care units in North America and Europe.Patients with severe sepsis or septic shock (n = 696) received standard supportive care and antimicrobial therapy for sepsis, in addition to rhIL-1ra or placebo.Patients were randomized to receive either rhIL-1ra (100 mg) or placebo (vehicle) by intravenous bolus, followed by a 72-hr continuous intravenous infusion of either rhIL-1ra (2.0 mg/kg/hr) or placebo.The study was terminated after an interim analysis found that it was unlikely that the primary efficacy end points would be met. The 28-day, all-cause mortality rate was 33.1% (116/350) in the rhIL-1ra treatment group, while the mortality rate in the placebo group was 36.4% (126/346), yielding a 9% reduction in mortality rate (p = .36). The patients were well matched at the time of study entry; 52.9% of placebo-treated patients were in shock while 50.9% of rhIL-1ra-treated patients were in shock at the time of study entry (p = .30). The mortality rate did not significantly differ between treatment groups when analyzed on the basis of site of infection, infecting microorganism, presence of bacteremia, shock, organ dysfunction, or predicted risk of mortality at the time of study entry. No excess number of adverse reactions or microbial superinfections were attributable to rhIL-1ra treatment in this study.A 72-hr, continuous intravenous infusion of rhIL-1ra failed to demonstrate a statistically significant reduction in mortality when compared with standard therapy in this multicenter clinical trial. If rhIL-1ra treatment has any therapeutic activity in severe sepsis, the incremental benefits are small and will be difficult to demonstrate in a patient population as defined by this clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MEMSforever发布了新的文献求助30
1秒前
酷波er应助吱吱采纳,获得10
6秒前
小鱼小鱼快快游完成签到 ,获得积分10
8秒前
蜜蜂威士忌完成签到 ,获得积分10
12秒前
bai1完成签到 ,获得积分10
18秒前
爆米花应助wowser采纳,获得10
18秒前
陈麦子完成签到,获得积分10
19秒前
小杨完成签到 ,获得积分10
22秒前
852应助水盒子采纳,获得10
23秒前
薰硝壤应助科研通管家采纳,获得10
27秒前
可爱香芦完成签到 ,获得积分10
34秒前
黑大侠完成签到 ,获得积分10
43秒前
璇璇完成签到 ,获得积分10
44秒前
50秒前
nano完成签到 ,获得积分10
52秒前
慕容飞凤完成签到,获得积分10
52秒前
勤奋千风完成签到 ,获得积分10
55秒前
philophysics完成签到,获得积分10
58秒前
Jaja完成签到,获得积分10
1分钟前
wushuimei完成签到 ,获得积分10
1分钟前
tt完成签到 ,获得积分10
1分钟前
1分钟前
Tim完成签到 ,获得积分10
1分钟前
Oct完成签到 ,获得积分10
1分钟前
1分钟前
皮皮球完成签到 ,获得积分10
1分钟前
黄金天下完成签到,获得积分10
1分钟前
北城完成签到 ,获得积分10
1分钟前
llhh2024完成签到,获得积分10
1分钟前
水盒子完成签到,获得积分10
1分钟前
i2stay完成签到,获得积分10
1分钟前
nt1119完成签到 ,获得积分10
1分钟前
成就的绮烟完成签到 ,获得积分10
1分钟前
月潮共生完成签到 ,获得积分10
1分钟前
果果完成签到,获得积分10
1分钟前
细心的代天完成签到 ,获得积分10
1分钟前
lululululululu完成签到 ,获得积分10
1分钟前
jxas完成签到,获得积分10
1分钟前
洁净青筠发布了新的文献求助10
1分钟前
Ethan完成签到 ,获得积分10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418298
捐赠科研通 2354492
什么是DOI,文献DOI怎么找? 1246104
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921